Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection

European Journal of Clinical Pharmacology

Volumn 61, Issue 5-6, 2005, Pages 375-379

  Gawrońska Szklarz, Barbara ^a   Wrześniewska, Joanna ^a   Starzyńska, Teresa ^a   Pawlik, Andrzej ^a   Safranow, Krzysztof ^a   Ferenc, Katarzyna ^a   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; GENOMIC DNA; GLYCOPROTEIN P; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE;

ADULT; AGED; ALLELE; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; GASTROESOPHAGEAL REFLUX; GENE FREQUENCY; H(+)-K(+)-EXCHANGING ATPASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; STOMACH ULCER; SULFOXIDES;

EID: 23844448269     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0901-1     Document Type: Article

References (32)

1. International Agency for Research on Cancer, World Health Organization (1994) Infection with Helicobacter pylori. In: Schistosomes, liver flukes and Helicobacter pylori. IARC, Lyon, pp 177-202
2. Soll AH (1996) Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology [review]. JAMA 275:622-629
3. Malfertheiner P, Megraund F, Morain CO et al (2002) Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Alim Pharmacol Ther 16:167-180
4. Janssen MJR, Van Oijen AHAM, Verbeek ALM et al (2001) A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitromidazole. Aliment Pharmacol Ther 15:613-624
5. Stedman CA, Barclay ML (2000) Review article: comparison of pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963-978
6. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17
7. Wedlund PJ (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61:174-183
8. Sapone A, Vaira D, Trespidi S et al (2003) The clinical role of cytochrome P450 genotypes in Helicobacter pylori management. Am J Gastroenterol 98:1010-1015
9. Pauli-Magnus Ch, Rekersbrink S, Klotz U, Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg's. Arch Pharmacol 364:551-557
10. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62:385-427
11. Wakasungi H, Yano I, Ito T et al (1998) Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 64:123-128
12. Wang L, Kitaichi K, Hui CS et al (2000) Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol 27:587-593
13. Chiou WL, Chung SM, Wu TC (2000) Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 17:903-905
14. Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478
15. Cascorbi I, Gerloff T, Johne A et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169-174
16. Siegmund W, Ludwig K, Giessmann T et al (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572-583
17. Haas CE, Lahiri DK, Bye S, Nurnberger JI Jr (1992) A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples that do nine other methods tested. J Biochem Biophys Met 25:193-205
18. Goldstein JA, Blaisdell J (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 272:210-217
19. De Morais SM, Wilkinson GR, Blaisdell J et al (1994) Identification of new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598
20. Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 29:192-209
21. Goldstein JA, Ishizaki T, Chiba K et al (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American Black populations. Pharmacogenetics 7:59-64
22. Meyer UA (1996) Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med 69:203-209
23. Meyer UA (1996) Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 8:S21-S25
24. Furuta T, Shirai N, Xiao F et al (2001) Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484-492
25. Furuta T, Shirai N, Takashima M et al (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin and clarithromycin. Clin Pharmacol Ther 69:158-168
26. Furuta T, Shirai N, Watanabe F et al (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453-460
27. 2-receptor antagonist. Aliment Pharmacol Ther 18:1149-1157
28. Tanigawara Y, Aoyama N, Kita T et al (1999) CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 66:528-534
29. Furuta T, Takashima M, Shirai N et al (2000) Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin Pharmacol Ther 67:684-689
30. Kawabata H, Habu Y, Tomioka H et al (2003) Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 17:259-264
31. Inaba T, Mizuno M, Kawai K et al (2002) Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 17:748-753
32. Aoyama N et al (2002) Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-it Helicobacter pylori therapy: pharmacokinetic considerations. Biol Pharm Bull 25:923-927